Lundbeck

A global biopharmaceutical company specialized in neuroscience

Bedrijfstype

Groot bedrijf


Sector

Geneeskunde / Farmaceutica / Gezondheid


Hoofdkantoor

Ottiliavej 9, 2500 Copenhagen, Denmark

Ontdek Lundbeck

Speel de video af
Video-voorbeeldafbeelding

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience. We discover, develop, and commercialize treatments that improve the lives of people affected by neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

We are 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks, or in the field, we work closely with patients, healthcare professionals, and the neuroscience community to uncover causes, find new treatments, and fight stigma and discrimination against people living with brain diseases.

We build on our Danish heritage and more than 70 years in neuroscience, fostering a culture of collaboration, responsibility, and respect.

For additional information, we encourage you to visit our corporate website www.lundbeck.com and connect with us via LinkedIn.

Hoe is het om te werken bij hen?

Neem een duik in het bedrijf

Speel de video af
Video-voorbeeldafbeelding

Living with chronic migraine - Hero Campaign

Speel de video af
Video-voorbeeldafbeelding

Lundbeck - World Mental Health Day 2021

  • Oprichtingsjaar

    1915

  • Gendergelijkheid

    46%

    54%

  • Internationale aanwezigheid

    50 landen

  • Waarden

    Patient-driven • Courageous • Ambitious • Passionate

Hun MVO-initiatieven

Al 3 acties voltooid 💚

  • Gender balance targets: min. 40% of underrepresented gender.

  • Reduction in scope 1 and 2 carbon emissions

  • Inclusive redesign of key people processes